[1] |
SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2019[J]. CA Cancer J Clin,2019,69(1):7-34.
|
[2] |
LUOMARANTA A,LEMINEN A,LOUKOVAARA M,et al.Magnetic resonance imaging in the assessment of high-risk features of endometrial carcinoma:a meta-analysis[J]. Int J Gynecol Cancer,2015,25(5):837-842.
|
[3] |
BRITTON H,HUANG L,LUM A,et al.Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma[J]. Gynecol Oncol,2019,153(3):487-495
|
[4] |
VALENTINIS B,BASERGA R.IGF-1 receptor signalling in transformation and differentitation[J]. Mol Pathol,2001,54(3):133-137.
|
[5] |
SEBASTIAN S,SETTLEMAN J, RESHKIN S J,et al.The complexity of targeting EGFR signaling in cancer: from expression to turnover[J]. Biochim Biophys Acta,2006,1766(1):120-139.
|
[6] |
魏丽惠. 重视子宫内膜癌的筛查[J]. 中华妇产科杂志,2013,48(12):881-883.
|
[7] |
BRAHMKHATRI V P,PRASANNA C,ATREYA H S.Insulin-like growth factor system in cancer:novel targeted therapies[J]. Biomed Res Int,2015,2015:538019.
|
[8] |
TU C,WANG F,WAN J.MicroRNA-381 inhibits cell proliferation and invasion in endometrial carcinoma by targeting the IGF-1R[J]. Mol Med Rep,2018,17(3):4090-4098.
|
[9] |
SHU S,LIU X,XU M,et al.MicroRNA-320a acts as a tumor suppressor in endometrial carcinoma by targeting IGF-1R[J]. Int J Mol Med,2019,43(3):1505-1512.
|
[10] |
SHU S,YANG Y,LI X,et al.Down-regulation of IGF-1R expression inhibits growth and enhances chemosensitivity of endometrial carcinoma in vitro[J]. Mol Cell Biochem,2011,353(1-2):225-233.
|
[11] |
LIVASY C A,READING F C,MOORE D T,et al.EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma[J]. Gynecol Oncol,2006,100(1):101-106.
|
[12] |
HALLE M K,TANGEN I L,BERG H F,et al.HER2 expression patterns in paired primary and metastatic endometrial cancer lesions[J]. Br J Cancer,2018,118(3):378-387.
|
[13] |
EJSKJAER K,SØRENSEN B S,POULSEN S S,et al. Expression of the epidermal growth factor system in endometrioid endometrial cancer[J]. Gynecol Oncol,2007,104(1):158-167.
|
[14] |
JIN Q,ESTEVA F J.Cross-talk between the ErbB/HER family and the type Ⅰ insulin-like growth factor receptor signaling pathway in breast cancer[J]. J Mammary Gland Biol Neoplasia, 2008,13(4):485-498.
|
[15] |
JONES H E,GODDARD L,GEE J M,et al.Insulin-like growth factor-Ⅰ receptor signalling and acquired resistance to gefitinib(ZD1839;Iressa)in human breast and prostate cancer cells[J]. Endocr Relat Cancer,2004,11(4):793-814.
|
[16] |
MORGILLO F,WOO J K,KIM E S,et al.Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib[J]. Cancer Res,2006, 66(20):10100-10111.
|